Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Short term Debt (2023 - 2024)

Oramed Pharmaceuticals (ORMP) has disclosed Short term Debt for 2 consecutive years, with $32.0 million as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, Short term Debt changed N/A year-over-year to $32.0 million, compared with a TTM value of $32.0 million through Mar 2024, changed N/A, and an annual FY2023 reading of $51.0 million, changed N/A over the prior year.
  • Short term Debt was $32.0 million for Q1 2024 at Oramed Pharmaceuticals, down from $51.0 million in the prior quarter.
  • Across five years, Short term Debt topped out at $75.4 million in Q3 2023 and bottomed at $32.0 million in Q1 2024.